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ABSTRACT

Leishmaniasis is a parasitic Neglected Tropical Disease (NTD) that affects mostly
poor countries of the third word due to their limited access to clean water and health
care. The disease is transmitted through the bite of a sand fly of the genus
Phlebotomus in the Old World, and of the genus Lutzomyia in the New World.

Historically, NTDs have not been given adequate attention or research funding and
finding curative treatments has been slow. However, the fact that the insect vector and
the parasite can live and thrive in any ecological system in the world, and under the
current circumstances of the world's worst refugee crisis playing a major role in the
geographical distribution of the disease, leishmaniasis has been given more attention.
Leishmaniasis is manifested in cutaneous or mucosal forms causing scan-ing,
disfiguration, bleeding and breathing difficulties, or in a visceral form that causes liver
and spleen malfunction, a compromised immune system and death if not treated.
Currently, there is no curative treatment or vaccination for leishmaniasis. The
available treatments aim to reduce morbidity from the cutaneous and mucosal
leishmaniasis, and mortality from the visceral fonn. Finding new medicines for
leishmaniasis requires identifying new drug targets, hence, gene function studies are
essential for revealing potential specific drug targets in this parasite.
Although the whole genomes of various leishmania species have been sequenced,
very little is known about the gene functions due to the absence of an RNAi pathway
in the parasite and the difficulty of achieving homozygous knock out (KO) by the
traditional homologous recombination methodology in a diploid organism like
leishmania. The new CRISPR/Cas9 technology for targeted gene editing holds great
promise for easier study of gene functions in leishmania, hence allowing identification
of new drug targets.
Very few studies were done on applying CRISPR/Cas9 in Leishmania. Therefore,
we attempted to adapt the CRISPR/Cas9 system to Leishmania donovani for a proof
of concept. In this research we describe a new culture medium not typically used in
the literature for L.donovani that allows optimal growth of promastigotes in vitro.
Also we describe protocols for genomic DNA extraction as well as oligonucleotide

annealing and cloning conditions adjusted specifically for the generation of gRNA
expression plasmids for leishmania. Furthermore, we established a stable Leishmania
cell line expressing Cas9, and set up the basic strategy for applying the CRISPR/Cas9
gene knockout technology

in L. donovani. After specifically targeting the ODC

(omithine decarboxylase) gene for KO, we found by DNA sequence analysis that no
Insertion or Deletion (lnDel) mutations occurred at the targeted site. This finding
indicates that although the Cas9 enzyme is likely to scan and cut the doublestranded
DNA frequently at the targeted site, the double strand breaks are being repaired
accurately each time by an error free repair machinery such as Homologous Directed
Repair. Thus, we propose as specific future direction the use of HDR for interruption
of the gene open reading frame instead of relying on simple Non-Homologous End
Joining for creating random InDels upon repairing the double stranded break by Cas9.
Overall, this study paved the way for adapting the CRISPR/Cas9 system to genome
editing in Leishmania, for future proof of concept and

gene function studies,

identification of new drug targets and possibly creating vaccinations by generating
attenuated Leishmania strains.
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CHAPTER ONE
INTRODUCTION

1.1. Leishmaniasis: A Neglected Tropical Disease

Leishmanisis along with other diseases such as lymphatic filariasis, dengue and
trachoma are categorized as Neglected Tropical Diseases (NTDs). NTDs affect mostly
poor countries of the third word due to limited access to clean water and health care.
Hence, historically, NTDs have not been given adequate attention or research funding
and finding curative treatments has been slow. These diseases take a tremendous toll
on the life of patients, physically, psychologically and socially. Whereas the maj01ity
of NTDs are not lethal, Leishmaniasis can be. Leishmaniasis is manifested in
cutaneous or mucosa! fonns causing scarring, disfiguration, bleeding and breathing
difficulties, or in a visceral fonn that causes liver and spleen malfunction, a
compromised immune system and death if not treated.
Finding new medicine for leishmaniasis requires identifying and evaluation new
drug targets, hence, gene function studies are essential for revealing potential specific
drug targets in this parasite. Although the whole genomes of various strains of
leishmania have been sequenced very little is known about its gene function. This is
due to the absence of an RNAi pathway in the parasite, thus allowing gene function
studies only by the traditional and laborious targeted gene knock out (KO) by
homologous recombination methodology (W. W. Zhang & Matlashewski, 2015). The
advent of CRISPR/Cas9 for easier targeted genome editing that can potentially expand
the possibility of studying gene function in leishmania. this would then allow
translational research to identify new drug targets, and/or to create attenuated strains
with multiple gene knock outs could form the basis for vaccination trials.
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1.2.The Disease
Leishmaniasis is a vector transmitted NTD that can be caused by 20 different species
the protozoan parasite Leishmania. Depending on the infectious strain, leishmaniasis is
manifested by a visceral fonn (kala-azar) that affects multiple internal organs such as the
spleen and liver; a cutaneous form that results in skin sores, and a subcutaneous form that
affects the mucous connective tissues. Of note is most people infected by the parasite do
not develop any symptoms at all in their life, therefore, the tenn '"leishmaniasis" refers to
the fact of becoming sick due to a Leishmania infection and not the mere fact of being
infected with the parasite. Cutaneous leishmaniasis (CL), a flesh-eating disease, is the
most common form of leishmaniaisis. CL is caused by the old world (Eastern
hemisphere) leishmanial species Leishmania tropica, L. major, and L. aethiopica, as well
as L. infantum and L. donovani, and the new world (western hemisphere) species
including L.mexicana species: L. mexicana, L. amazonensis, and L. venezuelensis and
the subgenus Viannia (L. braziliensis, L. guyanensis, L. panamensis, and L. peruviana).
Infected patients develop skin sores that tum to volcano-like ulcers with raised edges and
a central depression. Ulcers are generally painless but can be painful if infected with
bacteria or if the ulcer is located near a joint. Skin sores are accompanied by swollen
nearby lymphatic glands. Cutaneous lesions may self-heal or require treatment. The
subcutaneous (mucosa!) form of leishmaniasis (ML) may develop one to five years after
a cutaneous infection due to mucosa! dissemination of the parasite from skin lesions that
were not treated, or that were treated suboptimally. Mouth, nose and lip lesions develop,
and are accompanied by stuffy or runny nose, nose bleeding and breathing difficulty. If
not treated, a subcutaneous infection can result in ulcerative destruction of the nasooropharyngeal mucosa. Visceral leishmaniasis (VL) is the most dangerous form of
leishmaniasis. VL is caused by L. donovani and L. infantum. Clinical symptoms of VL
include spleen and liver enlargement, high fever, weight loss, low red blood cell count
(anemia), compromised immune system including low white blood cell and platelet
counts. Patients exhibit abnormal blood test results including a high total protein level
and a low albumin level, with hypergammaglobulinemia. Asymptomatic patients may
exhibit clinical manifestations years after infection upon becoming immunocompromised
2

due to other medical causes such as HIV co-infection. If untreated, VL is fatal either
directly or indirectly due to complications such as secondary mycobacterial infection or
hemorrhages.
The disease is transmitted from one infected person to another through the bite of an
infected phlebotomine sand fly. The insect vector is tiny in size, only 2-3 mm long. Only
female phlebotomine sand flies can transmit leishmaniasis, by feeding on human blood to
obtain proteins needed for its egg development. There are around 500 phlebotomine
species known worldwide, however, only around 30 species have been identified as being
a significant vector of Leishmaniasis. Once uptaken by the insect vector, the parasite
undergoes a major transformation that ranges between 4-25 days. After which, when the
infected sand fly feeds again on a new source of blood, it inoculates the parasite into the
new host through its proboscis, completing the transmission cycle (Figure 1.2).

1.3.Epidemiology

Leishmania parasites are found in about 90 countries in the tropical and
subtropical areas as well as southem Europe. The parasite and its insect vector can live
and thrive in a variety of ecological settings ranging from rain forests to deserts.
Climate change and population migration play an important role in expanding the
geographical area where leishmania and its insect vector are disseminated. According
to the World Health Organization (WHO) report about the epidemiology situation of
CL in 2015, Old world leishmania is most prevalent in Iran, Afghanistan, Syria and
Algeria where the number of reported new cases in 2013 exceeded 5000. Bangladesh,
Turkey, Iraq, Saudi Arabia, Yemen, Tunisia and Morocco have reported between
1000-4999 new cases in 2013. Inida, Bengladish, Ethiopia, Sudan, South Sudan (Old
world) and Brazil (New world) reported more than 1000 new cases in 2013. Somalia
and Iraq reported between 500 and 999 new cases in 2013. In the new world (the
Americas), CL is most prevalent in Brazil, Columbia and Peru where the reports
indicate more than 5000 new cases in 2013.

Panama, Nicaragua and Honduras

reported between I 000-4999 new cases in 2013 (WHO, 2017).
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Figure (1.1) : E pidemiological situation of Leihmaniasis (WH0,2013)
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1.4.Leishmania life cycle

Leishmanial parasites cycle between two mam life stages, promastigote and
amastigote. The infective form of the parasite called promastigote is transmitted to the
human host through the bite of infected female sand fly of the genus Phlebotomus in
the Old World, or of the genus Lutzomyia in the New World (Figure 1.2: step 1). The
parasite is phagocytized by macrophages and other mononuclear phagocytes and
transforms into amastigotes. During the amastigote stage of life, the parasite is
intracellular, non-motile, and its flagellum does not protrude further than the body surface
and cannot be distinguished by light microscopy. The amastigote cell size is
approximately 3-6 x 1.5-3.0 µm. Leishmania amastigotes live inside macrophages and
multiply by longitudinal binary fission at 37°C (Figure 1.2: Steps 2-4). On the other side,
a sand fly become infected with the parasite upon feeing on a blood meal from an
infected individual (Figure 1.2: Step 5). In the gut of the insect vector, amastigotes
develop into promastigotes at 27°C. The promastigote is an extracellular life stage,
during which the parasitic cell is motile through an anterior body flagellum, and grows
and multiplies by longitudinal binary fission. The promastigote cell size is roughly 15-30
x 5 µm. Once motile promastigotes migrate into the proboscis of the fly and become
ready to infect a new vertebrate victim (Figure 1.2: steps 6-8).

5

Human Stages

Sandfly Stages

Amas1igo1es multiply in cell<
of vanous tissues ;m1 m fcct
_ _ _.,...-~ other cei:s

A

0
A •1nl~e S1:>g<1

Sandlly l akes a blood meal
(•~' ~infloc:od
~-tl'l~~?QtM 1

A • Oo:>gnosbc St.'lJe

Figure 1.2: Leishmania Life cycle (Centers for Disease Control and Prevention, 2013)

Elimination of leishmanial infection from the body depends on a comb ination of factors
includ ing, but not limited to, the ability of leishrnania to fight and evade the immune
system, the immune status of the patient and possible co-infection w ith o ther pathogens
such as HIV.

1.5.Diagnosis and treatment options
Diagnosis of visceral leishmaniasis is challenging because its cli nical symptoms
are simil ar to those of other di seases such as malaria and tu berculosis. VL is
diagnosed by combining the observations of clinical man ifestations wi th laboratory
diagnosis, including parasite identification by light microscopy in stained specimens
of relevance, parasite D A detection in patient samples, and immunological testing.
W ith YL, specimens are taken from the spleen or bone man-ow to be exam ined, while
in CL, they are taken from skin lesions. Under the light microscope, amastigotes
appear in the cytoplasm of macrophages, where one can distingu ish the nucleus and
6

the rod-shaped kinetoplast by Giemsa stain (CDC). PCR is used to detect the parasite
DNA in patient samples. Primers targeting conserved sequences on the minicircles of
Kinetoplast DNA, allow not only the detection of the parasite, but also

species

identification (Celia Maria Ferreira Gontijo; Melo Norma Maria, 2002).
There is no vaccine, nor a curative treatment available for leishmaniasis. Current
therapy is attempted to lower mortality in visceral leishmanisis, and morbidity in both
cutaneous and mucosal leishmaniasis. The only Food and Drug Administration (FDA)
approved drugs for leishmaniasis are liposomal amphotericin B (L-AmB) which is
delivered intravenously for the treatment of visceral leishmaniasis and miltefosine
which is delivered orally for the treatment of cutaneous, mucosal and visceral
leishmaniasis, though both these treatments have a high risk of side effects such as
reproductive toxicity, ototoxicity, liver and renal failure. However, these treatments
are expensive and often unaffordable in poor countries. This is further compounded as
cheaper generic drugs are less effective and require lengthy treatments with more
toxic side effects. For prevention of leishmaniasis in travelers, no vaccines nor
chemoprophylaxis are currently available; personal protective measures to minimize
exposure to sand fly bites are recommended. Taken together, there is an urgent need
for new affordable anti-leishmanial medicines and chemoprophylactic agents for the
eradication and prevention of this severe disease (Aronson et al., 2016).
Finding new medicine for leishmaniasis requires identifying and evaluating new
drug targets, hence, gene function studies are essential for revealing potential and
specific drug targets in this parasite. Although the whole genomes of various strains of
leishmania have been sequenced very little is known about its genes function. This is
due to the absence of an RNAi pathway in the parasite, thus allowing gene function
studies only by the traditional and laborious targeted gene knock out (KO) by
homologous recombination methodology (W. W. Zhang & Matlashewski, 2015).
However, traditional a homologous recombination for homozygous gene knockout is
very difficult to achieve in a diploid organism like Leishmania, which some of its
chromosomes are even triploids and tetraploids. The advent of CRISPR/Cas9 for
easier targeted genome editing can potentially expand the possibility of studying gene
function in leishmania and this would then allow translational research to identify new
7

drug targets, and/or to create attenuated strains with multiple gene knock outs could
form the basis for vaccination trials.

1.6.CRISPR/Cas9 system
The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) - Cas9
system is a new powerful approach for genome engineering in mammalian cells, insects,
plants and other organisms. CRISPRs were first discovered in 1993 by the Spanish
microbiologist Francisco JM Mojica at University of Alicante in Spain. He suggested that
CRISPRs were used as a defense mechanism by bacteria against invading bacteriophages.
In January 2013, Feng Zhang, at the Broad Institute and MIT, published for the first time
his research on the use of the CRISPR/Cas9 system for genome editing in mouse and
human cells. The CRISPR/Cas9 technology can be used for creating gene knock-outs,
full or partial deletions, targeted insertions; even approaches for endogeneous gene
activation have been described. The native CRISPR/Cas9 system in Streptococcus
pyogenes consists of two short RNA molecules, CRIS PR RNA (crRNA) and trans

activating RNA (tracrRNA). CRISPR RNA (crRNA) is a variant oligonucleotide, whose
sequence is derived from the invading bacteriophage, while the conserved trans activating
RNA (tracrRNA) is derived from the bacterial cell (Figure 1.3). The tracrRNA is
essential for binding of the Cas9 endonuclease, while at the same time the crRNA
hybridizes to the target genome through a short homologous region, thereby guiding the
CRISPR complex to cleave the double stranded DNA.
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~Iodified

after Charpentier

&Doudna (Oregon Health & Science University, 2014). T he C RISPRJCas9 system is
co mposed of a chimeric guide RNA (sgRNA) which is a fusion or an invariable tracrRN/\
(yell ow) essential for bind ing the Cas9 enzyme, and a variable c rRNA (green) spec ific to the
ta rgeted sequence. Cas9 cndonuc leasc (purple) is guided by this sgRNA to the targeted gene,
recogn izing a PAl\1 sequence indicated as NGG (red), and generat ing a double stranded break in
the DNA double helix 3 nucleotides upstream of the PAM sequence. Desired editi ng at the DSB
site is then created based on the DNA repair mechanism used by the cel l.

To m1m1c this natural system fo r genome editing in other orgamsms, an m vitro
C RISPR/Cas9 system has been des igned. The system is composed of the Cas9
endonuclease enzyme and a single guide RNA mo lecule (sgRNA). The sgRNA bind to
the nuclease enzyme and lead it to create a double stranded DNA break (DSB) at the
targeted location. The sgRNA is a chi meric RNA molecule, composed of a variable 20nucleotide crRNA that is created specific to a targeted DNA sequence and fu sed to a
conserved 82 nucleotide tracrRNA seq uence. The 20-nucleotide guide RNA is followed
by a protospacer-adjacent motif (PAM) that is specifically recognized by the Cas9
enzyme. The canonical PAM sequence is 5'-NGG-3 ', where N can be any nucleotide.
Note that this sequence wi ll differ depend ing on the bacterial origi n of the Cas9 enzyme.
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The dsDNA cleavage is usually generated 3 bp upstream the PAM sequence. T he DSB is
then repaired either through an eITor prone repair mechanism called (N on-homology end
j oining (N HEJ), that results in random InDels rendering the gene non-functional, or
through an eITor free repair mechanism called Homology direct repair (HDR), that results
in faithful repair of the DNA damage.

1.7.Repair mechanisms of the double strand break generated by Cas9 endonuclease
Non-homologous end joining (NH EJ) is the principle means by which ori ginal
CRISPR/Cas9 double strand breaks are repaired because it is the most prevalent type of
DNA repair approach that is active at all times throughout cel l cycle. It takes much less
time than Homology Directed Repair (HOR) as it functions without the presence of a
repair template such as a sister chromatid or other DNA homologue. Therefore, in the
simple CRISPR/Cas9 system , a D SB at a targeted site is repaired by N H EJ resulting in
small insertions or deletions (INDELs) that causes gene knock out (gene product loss of
functi on).

I

-
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l
Error free repair based
on long nanking
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Repair w ith deletion between
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One microhomology region
retain ed

Figure 1.3: Double stranded break repair mechanisms (Gearing, 2016)

Another mechanism for DNA repair is Microhomology-Mediated End Joining (M M EJ),
where small (5-25) flanking m icrohomology regions contribute to defining the location
10

where the broken ends will be ligated. In this context, MMEJ is not as precise as HDR,
yet it is much more predictable and protective than NHEJ . A study by (W. W. Zhang &
Matlashewski, 2015) suggested that HDR is the dominant repair mechanism in
leishmania, with MMEJ occuning in fewer instances.
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Figure 1.4 : Polyamine synthesis pathway in Leishmania (Colotti & Ilari, 2011)

Since this study aim to provide a proof of concept by showing the ability to use
CRISPR/Cas9 system for studying gene function, we chose a leishmanial gene that has
been relatively extensively studied in the literature. The Ode gene has been amplified,
cloned and sequenced fo r the first time in 1992 by (Hanson, Adelman, & Ullman, 1992),
while its function was extensively studied using traditi onal gene repl acement approaches
in vivo and invitro as discussed below. In this context, Ode gene is suitable for testing
and adapting the new strategy of gene knock out using CRISPR/Cas9 approach and
where it is simply required to achieve similar results as in the traditional gene knock out
approach. Ode is a gene that has been studied relatively extensively by traditional
targeted gene knock out. The Omithine Decarboxylase enzyme is a criti cal component of
11

the polyamine synthesis pathway in leishmania. This protein contributes to the production
of polyamines (putrescine and spermidine) that are essential for the survival of the
parasite as well as its ability to fight the immune system by inhibiting the production of
NO. Polyamine synthesis pathway starts with arginine being converted into L-omithine,
after which ODC converts L. omithine into putrescine, which in tum is converted into
spermidine through spermidine synthase (SpdS) (Figure 1.4). Leishmania, like
mammalian cells are auxotrophs for arginine, in which case the intracellular parasite will
compete with its host macrophage cell on this amino acid to use it in polyamine synthesis
. Polyamines are positively charged compounds that interact with DNA and RNA
directly, and therefore they play a crucial role in regulating cell proliferation and
differentiation. Furthermore, polyamines are also involved in other macromolecular
production such as thiol trypanothione(Colotti & Ilari, 2011) which is essential for the
parasite survival once it reaches the blood stream of the human host. Thiol trypanothione
is a molecule specific to trypanosomatides, including leishmania, and is composed of two
glutathione molecules joined by a spermidine polyamine linker. The majore function of
thiol trypanothione is defense against oxidative stress applied by the human immune
system in an effort to eliminate the infective parasite. Once the leishmania promastigotes
reches the blood stream of the human victim, an immune response is generated. An
important aspect of this immune response is the production of nitric oxide (NO) by a
variety of immune cells that help eradication of the infecting leishmania. NO is a free
radical with anti-microbicidal activity against a wide range of bacteria and intracellular
parasites including leishmania. The free radical NO is synthesized by NO synthase, by
converting L-arginine into L-citrulline. NO along with superoxide (02- ) forms
peroxynitrite (ONOO-), which is a potent oxidizing agent that can react with a number of
different molecules including DNA, proteins and lipids leading to their severe damage
and resulting cytotoxic effects (Habib & Ali, 2011). However, leishmanial parasites can
inhibit the production of NO via multiple pathways, allowing them to escape the immune
system and establish an infection. Also, when a parasite enters a macrophage, it forms a
parasitophorous vacuole, a structure produced by parasites of the apicomplexan phylum
of parasites including Leishmania in the cells of the host, that allows the parasite to
develop while protected from lysosomes and NO effects. In this context, it is not a
12

surprise that inhibiting nitric oxide species production by thiol trypanothione in
leishmania is a major defense mechanism which determine if the parasite will be able to
establish an infection or will be cleared out from the system(Colotti & Ilari, 2011 ). A
targeted gene replacement study (Jiang et al., 1999) showed that a homozygous L1odc
L.donovani strain exhibits polyamine auxotrophy, a situation in which promastigotes

cannot survive in a culture that lacks polyamines. The study also showed that this
phenotype can be rescued by the addition of the readily available polyamines putrescine
or spermidine to the medium. Hence, this study further suggested that the Ode gene is
essential for parasite survival. An in vivo study (Boitz et al., 2009) showed that a
homozygous L1odc strain of L.donovani is able to scavenge polyamines from the
surrounding medium yet only at levels that do not allow it to sustain infection in the
animal model. Ornithine Decarboxylase enzyme is thought to be a potential drug target
for L.donovani and L.infantum. In fact, a-difluoromethylomithine (DFMO), a fluorinated
ornithine analogue, is used for the treatment of African sleeping sickness caused by the
parasitic kinetoplastid Trypanosoma brucei by irreversibly inhibiting ODC enzyme
(Colotti & llari, 2011 ).
In this context, the ode gene is an essential gene for leishmania survival and
infectivity, and is potential drug target. In this study, we attempt to generate Ode gene
KO by interrupting the open reading frame using CRISPR/Cas9 system. The goal of this
study, is to introduce and optimize CRIPR/Cas9 to L.donovani for gene editing in order
to facilitate future gene function studies in this parasites.
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CHAPTER TWO
MATERIALS AND METHODS

2.1. Leishmania strain and culture medium
The Leishmania donovani 1S strain (MHOM/SD/62/1 S), NR-48821, used in this
study was obtained from BEI Resources, NIAID, NIH. Schneider's Drosophila Medium
supplemented with 10% fetal calf serum, 10% sterile-filtered human male urine and 40
ug/ml gentamicin was used for routine culturing of promastigotes at 26°C. Cultures were
passaged to fresh medium in a 1:50 dilution every 3-4 days.

2.2. Genomic DNA extraction, target gene sequence confirmation using PCR and
Sanger Sequencing analysis
Genomic DNA was extracted from wild type (WT) L.donovani promastigotes.
Parasites were grown into mid log-phase, a total of 15 x 106 cells were pelleted, and
DNextraction proceeded using the Qiagen DNeasy Blood & Tissue Kit according to the
manufacturer's instructions.

The genomic sequence of the targeted Ode gene was

retrieved from the literature and primer sets for PCR amplification were designed
accordingly

(ODCFl:

CTCTGCATTCCGCACAGACC,

ODCF2:

CAAG

GAAGAAATAC ATATGGTGC, ODCRl: ACTGATCTT TTCCATCTCC AGC,
ODCR2: GGACGA GCACACCCTA CAGC), where (ODCFl, ODCRl) target the 5'half of the gene, (ODCF2, ODCR2) target the 3'- half of the gene and (ODCFl, ODCR2)
target the whole 2kb gene sequencePCR Using Q5® High-Fidelity DNA Polymerase
(M0491) from was performed according to the following conditions: 30 sec initial
denaturation at 98oC; 25 cycles of denaturation (10 sec at 98 °C), annealing (30 sec. at
65°C), and extension (1 min. at 72 °C); a final extension at 72 °C for 2 min. PCR
amplification products were visualized on a 0. 7% agarose gel electrophoresis for quality
control. The full length amplified gene fragment was gel purified using the QIAquick Gel
Extraction Kit, and sent for sequencing at the Biology department at Montclair State
University. The same procedures were used to verify deletions generated in the gene after
electroporation with both pLPhygCAS9 and pSPneogRNAH plasmids and selection.
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2.3. Plasmid constructs
Plasmid constructs pLPhygCAS9 and pSPneogRNAH were a gift from Greg
Matlashewski (Addgene plasmid # 63555 and # 63556 respectively). pLPhygCAS9
expresses humanized Cas9 enzyme with a nuclear localization signal and contains a
Hygromycin resistance gene as selection marker. The pSPneogRNAH plasmid contains
the L. donovani rRNA promoter followed by the guide RNA sequence insertion sites
(Bbsl) and the tracrRNA sequence, followed by the HDV ribozyme coding sequence
which self-cleaves the gRNA at its 3' end. G418 resistance is conferred by the neomycin
selection marker in this plasmid when expressed in the parasite.

2.4. crRNA and primer design and synthesis
The crRNAs were designed manually and with the crRNA designer tool
(http://www.e-crisp.org/E-CRISP/), then verified for significant on and off target matches
within

the

L.

donovani

genome

via

(http://protists.ensembl.org/Leishmania donovani bpk282al/Tools/Blast?db=core).
The primers for PCR were designed manually, synthesized and purchased from
Invitrogen.

2.5. Cloning guide RNA sequences into various gRNA expression vectors
The complementary single stranded oligonucleotides for crRNA were annealed in
lX Buffer 3 (New England BioLabs), by heating the mix to 95 °C for 4 min, followed by
cooling down back to 20°C at a rate of 0.1°C per second using a thermocycler. Annealed
oligonucleotides form the necessary Bbsl overhangs so no restriction digestion is
necessary for the oligoes, but only the plasmids will be digested with Bbsl.
pSPneogRNAH plasmid DNA was digested with Bbsl restriction enzyme at 37 °C for 1
hour. Digestion was validated on a 0. 7% agarose gel electrophoresis. Digested plasmid
was then gel purified using the QIAquick Gel Extraction Kit. The various annealed
crRNA oligonucleotides were cloned into the digested and purified plasmid in the
presence of T4 DNA ligase, purchased from New England BioLabs, at l 6°C for 4 hours.
Recombination products were transformed into One-Shot MAX Efficiency DH5-TIR
Competent Cells purchased from Invitrogen.
15

2.6. Verification of crRNA insertion and clonal amplification
Three clones were chosen from each ligation. Transformed cells were grown overnight in
4ml LB broth containing carbenicillin. Plasmid mini-preps were performed for each of
the 21 cultures using the QIAprep Spin Miniprep Kit. The presence of an insert was
verified by: first, PCR amplification using reverse primer (pSPneogRNAH R=
OTOACAACOTCOAOCACAOC) and the forward single stranded crRNA relevant to
each construct as a forward primer. Also, Sanger Sequencing was performed to verify the
exact crRNA insert sequence in each clone.
2.7. Leishmania Transfection and selection.
A two- plasmid strategy was used in this study one plasmid that carries the Cas9
encoding gene (pLPhygCAS9), and one plasmid carries the gRNA encoding oligos
(pSPneogRNAH). First, WT L.donovani was transfected with pLPhygCAS9 as described
in (Robinson & Beverley, 2003). Briefly, promastigotes were grown to mid-log phase.
Cells were pelleted at 1300

x

g for 10 min and washed in half of the original volume with

electroporation buffer (EB) (120 mM KC12, 0.15 mM CaC12 ,10 mMK2HP04, 25 mM
HEPES, 2 mM EDTA, and MgC12; pH 7.6). Cells were pelleted again at 1300
min. The pellet was resuspended in EB to a final concentration of 2

x

x

g for 10

8

10 cells/ml. 10 ug

of plasmid construct was aliquoted into a 4-mm gap cuvette. 500 ul of cells were added to
the cuvette and mixed. Using a Biorad OenePulser Xcell electroporator the cells were
electroporated twice at 25 uF, 1500 V (3.75 kV/cm), pausing 10 s between pulses. Cells
were incubated at 26°C for 48 hrs. to recover without antibiotic pressure. Selection
started 48 hrs post electroporation for three weeks in culture medium containing 100
ug/ml hygromycin. The created Cas9 expressing L. donovani strain was subsequently
transfected with various combinations of gRNA expressing constructs, selected with
0418 (100 ug/ml) for 3-4 weeks and maintained continuously in medium containing both
hygromycin and 0418 (100 ug/ml each).
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2.8. Western Blot Analysis.
Western blot was performed to confirm the constitutive expression of Cas9 in the
selected promastigotes. At mid-log phase of growth, cells were collected and lysed using
Bacterial Protein Extraction Reagent (B-PER) with proteinase inhibitor. Lysed cells were
centrifuged, and samples were taken from supernatant. 40 x 106 cells/well was used as
starting material. Anti-flag primary antibody raised in mice, AP-linked anti-mouse
secondary antibody and AP-chromogenic substrate were used for detection. An anti atubulin primary antibody was used to detect actin as a loading control.

2.9. Selection on Chemically defined medium
The polyamine deficient, chemically defined medium DMEL-CS was prepared
according to (Iovannisci & Ullman, 1983), with replacing Bovine serum albumin with
Chicken Serum (Table 2.1 ). Polyamine spermidine was added when indicated to rescue
L.donovani promastigotes with an Ode gene KO.

Table 2.1. Composition of DMEL-CS
--

- - - - - - - - - - - - - - - - - - - - - - - - - - . . ------·

Components*

·-

Amount per liter

Ph

----------··-----···------~-- -----~----····------·-······-··----------

Dulbecco's Modified Eagle powder (DME)
-

-~--··--·

--- -

NaHC03
---

.

13.45 g

-- ·----- -- ------------

3.7 g

-··--------·-

Tween-80

40mg

Hem in

5mg

Biotin

1 mg

Chicken Serum
-----·-·------------~----

10% volume

·--------- - - - - - - - -

-

-----------

Xanthine
- - - - - - - ---------·----.

HEP ES

0.1 Mm
. ..

·- ---------- - -------·---

-··-~

10 g

7.0

*All components were pre-prepared as sterile concentrated stocks, and stored at 4°C.
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CHAPTER THREE
RESULTS

3.1. Growth Characteristics of Leishmania donovani in the complete complex
Schneider's Drosophila medium
The use of our complete Schneider's Drosophila medium enabled a rapid
exponential promastigote growth that peaked at day 4 when the culture density reached
-93x106 Cells/ml (figure 3.1). Cultured promastigotes displayed healthy and expected
characteristics as referred to in the literature:

during log phase of growth, healthy

promastigotes looked flagellated, had a drop-like shape, were motile, and cells
undergoing binary fission were abundant. At the stationary phase cells showed a more
elongated body shape, became less motile, no multiplying cells were seen and a lot of
debris resulting from cell death was found in the medium. This medium is not typically
used in the literature for culturing Leishmania species, but was developed through this
study in our lab. The medium showed better quality and consistency in growing leishmaia
promastigotes than the complete Ml 99 medium described in the literature under our
laboratory's conditions (data not shown).
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Figure 3.1. L.donovani Growth Curve in Complete Schneider's Drosophila Medium.

....

Ii

18

3.2. The Sequence of the Ode gene from our lab L. donovani strain is identical to the
sequence from the literature and databases
According to the TriTryp DB for Kinetoplastid Genom ic Resources, ornith ine
decarboxylase in the L. donovani BPK282A 1 reference strain is located on chromosome
12 (LdBPK_ 120 l 05 .1) as a single copy gene. The gene consists of one ex on, 2124 bp in
length, encoding an ODC protein that is 707 amino acids in length. The genomic
reference sequence of Ode was obtained from Genbank (entry M81 l 92) . 4 primers were
designed to target this sequence (ODCFl , ODCF2, ODCR 1 AND ODCR2); where
(ODCF1, ODCR l) amplify the first half of the gene, (ODCF2, ODCR2) amplify the
second half of the gene and (ODCF1, ODCR2) amplify the whole 2kb gene sequence.
PCR amplification resulted in sharp clean bands with the expected sizes, indicating that
the target gene is indeed a part of our lab' s L.donovani strain. Sanger sequencing results
covered -80% of our amplified gene, showing an exact match throughout the sequenced
nucleotides.

B

MM

2

3

Figure 3.2. PCR amplification product of Ode gene yielded clean bands with the expected
sizes molecular weight. A. Whole genomic DNA extract form L.donovani visualized on 0.7%
agarose gel electrophoresis showing intact genomic DNA with no degradation. B . PCR
amplification products showing clean single bands at - 2kb for DNA sample amplified using the
primers pair (ODCFI and ODCR2, Jane 1) targeting the fu ll length of Ode gene. Single band
resulting from amplification of the first half of Ode using primer pair (ODCF I and ODCR 1, Lane
2), Single band resulting from amplification of the second half of Ode using primer pair (ODCF2
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and ODCR2, Lane 3). 1kb DNA ladder purchased from New England BioLabs was used in each
experiment (MM=Molecular Marker).

3.3. Establishing a stable L. donovani strain that expresses Cas9 endonuclease
constitutively
In order to facilitate CRISPR/Cas9, a stable cell line has been established by
episomal expression of Cas9 expressed off the plasmid

pLPhygCAS9. After

electroporation, cells were left to recover for 48 hours, at which time point selection
started by addition of 50 and/or 100 ug/ml of hygromycin. After growing cells under
antibiotic pressure for 3 consecutive weeks, western blot analysis was done to verify the
expression of Cas9 endonuclease in the selected pool of promastigotes.

1

Cas9 "'160 _ . .

160 KO
110 KO
60 KO

40 KO

Figure 3.4. Western blot analysis showing expression of Cas9. Lane 1 indicate a molecular
weight marker. Lanes 2 and 3 are wild type samples showing no Cas9 expression, lanes 4 and 5
are derived from cultures selected on 100 ug/ml of hygromycin for 26 days, lanes 6 and 7 are
derived from cultures selected for on 50 ug/ml of hygromycin for 2 1 days. Lanes 2,4 and 6
contain lysate equivalent to 20x I 06 cells as starting material, whereas Janes 3,5 and 7 contain
lysate equivalent to 40x 106 cells as starting material.
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3.4. Cloning the various crRNAs into pSPneogRNAH vectors and verification of
correct insertion.
Correct insertion of each crRNA was verified by PCR using reverse primer
(pSPneogRNAH R= GTGACAACGTCGAGCACAGC) and the forward single stranded
crRNA relevant to each construct as a forward primer. Also, Sanger sequencing was used
for further verifying the exact crRNA insert sequence in each clone (data not shown).

3.5. No InDels generated by CAS9 cleavage throughout the Ode gene
Genomic DNA from each sample as well as WT sample was extreacted, and OdC
gene 2kb was Amplified by PCR. The amplicon was then gel purified and sent for
sequencing. Sequencing analysis of Cas9 expressing L. donovani that were co-transfected
with a sgRNA constructs showed no insertion or deletion occurring at the targeted site of
Cas9 (Figure 3.5) indicating that the cleavage generated by Cas9 was repaired by
Homology Directed Repair mechanism (HDR). These results are consistent with (W. W.
Zhang & Matlashewski, 2015) which suggested the dominance of HDR and the absence
ofNHEJ in Leishmania as opposed to mammalian cells.
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Figure 3.5: DNA sequencing analysis shows no InDels generated by CAS9 cleavage
throughout the Ode gene. First line of each figure show the reference Ode sequence according to
which crRNA sequences were designed, second line of each figure indicate the sequence
generated after the double plasmids transfection and selection under antibiotic pressure for 3-4
weeks. For all samples. For all samples A through D, sequence ana lysis shows no de letion or
insertion generated at the expected cleavage site by Cas9 guided by the specific indicated gRNA.
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3.7. Chemically defined media DMEL-CS needs further optimization to support L.

donovani growth.

In hypothesis, if we were capable to produce Ode gene knock out, L.donovani
promastigotes will become auxotroph for polyamines putrescine and spermidine.
Therefore, the KO will be lethal in the absence of readily available Polyamines in the
medium. To test our hypothesis, we prepared a chemically defined medium, to which we
can add or eliminate polyamines. In theory, in the absence of polyamine from this
medium, wild type strain should be able to grow healthily and indefinitely, while the KO
strain will not be able to survive unless spermidine or putrescine is added. Although the
chemically defined medium was prepared and optimized according to literature
resources, it was only able to support growth and proliferation of L. donovani WT for 3
consecutive passages. At first, promastigotes displayed healthy cellular characteristics
including cell morphology and motility, however, a gradual decrease in doubling rate was
noticed where a culture took 6 days instead of 3-4 days to reach maximum density. After
the 3rd passage, the cells looked less motile and more rod-like shaped, and eventually
stopped proliferating. Hence, the DMEL-CS medium as we prepared it still requires
further optimization to support indefinite L. donovani WT strain growth before it is used
for further characterization of a KO strain.
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CHAPTER FOUR
DISCUSSION

Under the current worst refugee crisis in history, and as a neglected tropical
disease that is most prevalent in poor countries, Leishmaniasis requires urgent
development of curative medicines and vaccination. Drug and prophylaxis development
in turn require more in depth knowledge about the causative agent as well as the vector
transmitting the disease. For a long time, studying leishmanial gene function was very
difficult due to the absence of the RNAi pathway in the parasite, making the study of
gene function difficult, requiring the use of the tedious traditional approach of gene
replacement by homologous recombination.
In the last decade, the CRISPR/Cas9 system has been optimized for gene

knockout/knockin approaches in mammalian cells, plants and even insects. However,
very little research has been done on adapting this system in studying Leishmaia. Since
there are core differences between applying CRISPR/Cas9 in Leishmania and
mammalian cells, in this study we attempted to develop and optimize a basic
CRISPR/Cas9 system in our lab for targeted gene knock out in order to facilitate future
gene function studies in Lesihmanial parasite.
Over the course of this research, we were able to optimize a culture medium for
growing promastigotes of L.donovani in our lab (Figure 3.1). The medium described here
was not typically used in the cultivation of Leishmania in the literature, but rather
adjusted by collaborative efforts of our lab members. This medium showed better growth
characteristics, higher peak density and more consistency in growth rate and passages
intervals under our laboratory's conditions, than complete Ml 99 mediums described in
the literature. Since there is no kits available specifically for genomic DNA purification
from Leishmania, we used a kit for genomic DNA extraction from human and we made
necessary modifications to make compatible with DNA extraction from the parasite. With
our easy modified protocol, we were able to obtain high quality and quantity of DNA that
24

has been validated by agarose gel electrophoresis and nanodrop. Also, cloning
oligonucleotides encoding gRNAs into an expression vector, PCR and electroporation
conditions were modified for serving the purpose of applying CRISPR in L.donovani in
our lab settings. s
In this study, we aimed to apply the simplest CRISPR/Cas9 system to generate a
basic understanding about its adaptability to leishmania. Hence, theoretically, an
introduced Cas9 in promastigotes will generate DNA double stranded breaks at the
targeted site, which will then be repaired by the most prevalent repair machinery NonHomologous End Joining (NHEJ), which will result in random insertion and/or deletion
events while repairing the damage. interruption of the open reading frame with InDels
would render the mutated gene product nonfunctional, and therefore the resulting
phenotype can be characterized.
To facilitate the applying the above described CRISPR/Cas9 in L.donovani, we
used two plasmids strategy where a stable promastigote cell line expressing Cas9 was
created at first by shuffling in an episom carrying the Cas9 encoding gene. Hence, we
were able to create a stable line of L.donovani promastigotes that expresses Cas9
endonuclease constitutively, expression was confirmed at 6 and 11 passages. Then, we
designed multiple sgRNA constructs with which we attempted to target the Omithine
Decarboxylase gene and interrupt its open reading frame (ORF); the resulting gene knock
out should facilitate a classical reverse genetic way to study its function. The next step,
was transfecting the second plasmid which carries the sgRNA encoding segment and
selecting tranfectants for up to four weeks under antibiotic pressure. However, DNA
analysis indicated no InDel mutations occurring at the targeted site. This finding probably
indicates that although Cas9 enzyme is scanning and cutting the dsDNA frequently at the
targeted site, the double strand breaks are being repaired accurately each time by an error
free repair machinery such as Homologous Directed Repair. These results are consistent
with previeous studies by (W. W. Zhang & Matlashewski, 2015) and(W. Zhang,
Lypaczewski, & Matlashewski, 2017) that have reported the dominance of HDR
mechanisms in the absence of Non-Homologous End Joining (NHEJ) in Leishmania
when compared to mammalian cells. In fact, since Leishmania is a diploid organism, and
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some of its chromosomes are even triploid and quadraploid, HDR by interchromosomal
recombination is not unexpected.
Future directions for this research could include taking advantage of the HDR
dominance in the parasite by co-transfecting a stop codon cassette donor oligonucleotide
along with the gRNA construct. The donor in this approach would have flanking arms
that are homologous to the expected Cas9 cleavage site on the DNA and therefore can be
inserted into the ORF at the targeted location. Hence, the expected accurate insertion of
the Stop codon cassette at the cleavage site, could potentially result in a prematurely
terminated translational product that is equivalent to a gene knock out. Another approach
can be targeting two sites in the gene with two specific gRNAs along with a stop codon
cassette donor with flanking arms that are homologous to the expected Cas9 cleavage site
where the donor can help joining the two cleaved sites and generating a deletion in the
gene at the same time, thus increasing the possibility of introducing a KO mutation. Such
a mutation can again result in a truncated protein that would be non-functional and thus
enable the study of the phenotype resulting from this gene function by reverse genetics
means.
Also, it would be important to follow up such a study with whole genome
sequencing of the mutated strains, to look for possible off-target mutations that may have
occurred across the genome. As has been shown in previous studies, the SpCas9 enzyme
can lead to undesired off target mutations that can confound the experimental outcome.
Furthermore, the Cas9 enzyme used in this study is codon optimized for use in human
cells, so there could be some bias when it is being used in Leishmania due to codon
translational differences between the two organisms. Cas9 variants are being used for
their enhanced specificity such as Cas9 Nickase, which generates a single strand break,
along with a repair template, therefore taking the most advantage of HDR in Leishmania
to increase specificity.
Another difference to the mammalian system is the use of the human U6
promotor (RNA Polymerase III) to drive gRNA expression . However, this promotor has
not been characterized in Leishmania, therefore, the ribosome RNA promotor (RNA
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Polymerase I promotor) can be used instead in leishmnaia (W. W. Zhang &
Matlashewski, 2015).
In summary, in this study we optimized culture medium for L.donovani and
protocols for genomic DNA extraction as well as annealing and cloning conditions. We
established a stable cell line expressing Cas9, and set up the basic strategy for applying
CRISPR/Cas9 in leishmania. Overall, this study paved the way for adapting
CRISPR/Cas9 system for genome editing for future proof of concept, gene function
studies and identifying new drug targets and creating vaccination.
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